Benowitz NL - Search Results

1

Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake.

Zhu AZ, Zhou Q, Cox LS, Ahluwalia JS, Benowitz NL, Tyndale RF. Zhu AZ, et al. Among authors: benowitz nl. PLoS One. 2013 Aug 2;8(8):e70938. doi: 10.1371/journal.pone.0070938. Print 2013. PLoS One. 2013. PMID: 23936477 Free PMC article.

2

Deficient C-oxidation of nicotine continued.

Benowitz NL, Griffin C, Tyndale R. Benowitz NL, et al. Clin Pharmacol Ther. 2001 Dec;70(6):567. doi: 10.1067/mcp.2001.120252. Clin Pharmacol Ther. 2001. PMID: 11753274 No abstract available.

3

Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.

Dempsey D, Tutka P, Jacob P 3rd, Allen F, Schoedel K, Tyndale RF, Benowitz NL. Dempsey D, et al. Among authors: benowitz nl. Clin Pharmacol Ther. 2004 Jul;76(1):64-72. doi: 10.1016/j.clpt.2004.02.011. Clin Pharmacol Ther. 2004. PMID: 15229465

4

Pharmacogenetics of nicotine metabolism in twins: methods and procedures.

Swan GE, Benowitz NL, Jacob P 3rd, Lessov CN, Tyndale RF, Wilhelmsen K, Krasnow RE, McElroy MR, Moore SE, Wambach M. Swan GE, et al. Among authors: benowitz nl. Twin Res. 2004 Oct;7(5):435-48. doi: 10.1375/1369052042335269. Twin Res. 2004. PMID: 15527659

5

Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence.

Swan GE, Benowitz NL, Lessov CN, Jacob P 3rd, Tyndale RF, Wilhelmsen K. Swan GE, et al. Among authors: benowitz nl. Pharmacogenet Genomics. 2005 Feb;15(2):115-25. doi: 10.1097/01213011-200502000-00007. Pharmacogenet Genomics. 2005. PMID: 15861035

6

Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy.

Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tyndale RF. Malaiyandi V, et al. Among authors: benowitz nl. Mol Psychiatry. 2006 Apr;11(4):400-9. doi: 10.1038/sj.mp.4001794. Mol Psychiatry. 2006. PMID: 16402128 Clinical Trial.

7

Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics.

Al Koudsi N, Mwenifumbo JC, Sellers EM, Benowitz NL, Swan GE, Tyndale RF. Al Koudsi N, et al. Among authors: benowitz nl. Eur J Clin Pharmacol. 2006 Jun;62(6):481-4. doi: 10.1007/s00228-006-0113-3. Epub 2006 Apr 28. Eur J Clin Pharmacol. 2006. PMID: 16758265

8

Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation.

Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, Benowitz N. Lerman C, et al. Clin Pharmacol Ther. 2006 Jun;79(6):600-8. doi: 10.1016/j.clpt.2006.02.006. Epub 2006 May 11. Clin Pharmacol Ther. 2006. PMID: 16765148 Clinical Trial.

9

Guidelines on nicotine dose selection for in vivo research.

Matta SG, Balfour DJ, Benowitz NL, Boyd RT, Buccafusco JJ, Caggiula AR, Craig CR, Collins AC, Damaj MI, Donny EC, Gardiner PS, Grady SR, Heberlein U, Leonard SS, Levin ED, Lukas RJ, Markou A, Marks MJ, McCallum SE, Parameswaran N, Perkins KA, Picciotto MR, Quik M, Rose JE, Rothenfluh A, Schafer WR, Stolerman IP, Tyndale RF, Wehner JM, Zirger JM. Matta SG, et al. Among authors: benowitz nl. Psychopharmacology (Berl). 2007 Feb;190(3):269-319. doi: 10.1007/s00213-006-0441-0. Epub 2006 Aug 9. Psychopharmacology (Berl). 2007. PMID: 16896961 Review.

10

CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.

Benowitz NL, Swan GE, Jacob P 3rd, Lessov-Schlaggar CN, Tyndale RF. Benowitz NL, et al. Clin Pharmacol Ther. 2006 Nov;80(5):457-67. doi: 10.1016/j.clpt.2006.08.011. Clin Pharmacol Ther. 2006. PMID: 17112802 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

803 results

Search Page